[go: up one dir, main page]

MX2017003063A - Prueba de diagnostico basada en fragmento de rgma. - Google Patents

Prueba de diagnostico basada en fragmento de rgma.

Info

Publication number
MX2017003063A
MX2017003063A MX2017003063A MX2017003063A MX2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A
Authority
MX
Mexico
Prior art keywords
diagnostic test
test based
rgma fragment
rgma
methods
Prior art date
Application number
MX2017003063A
Other languages
English (en)
Other versions
MX385216B (es
Inventor
Barghorn Stefan
Striebinger Andreas
Schmidt Martin
Klaus MÜLLER Bernhard
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MX2017003063A publication Critical patent/MX2017003063A/es
Publication of MX385216B publication Critical patent/MX385216B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)

Abstract

Se proveen pruebas de diagnóstico y métodos para utilizar las pruebas de diagnóstico para detectar y cuantificar fragmentos de RGMa en una muestra. Los métodos se pueden utilizar en la detección de los fragmentos de RGMa para monitorear el tratamiento con fármaco y la efectividad del tratamiento con fármaco en enfermedades neurodegenerativas.
MX2017003063A 2014-09-10 2015-09-09 Prueba de diagnostico basada en fragmento de rgma. MX385216B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048745P 2014-09-10 2014-09-10
PCT/EP2015/070603 WO2016038084A1 (en) 2014-09-10 2015-09-09 Rgma fragment based diagnostic assay

Publications (2)

Publication Number Publication Date
MX2017003063A true MX2017003063A (es) 2017-06-14
MX385216B MX385216B (es) 2025-03-14

Family

ID=54064367

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003063A MX385216B (es) 2014-09-10 2015-09-09 Prueba de diagnostico basada en fragmento de rgma.
MX2021009528A MX2021009528A (es) 2014-09-10 2017-03-08 Prueba de diagnostico basada en fragmento de rgma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009528A MX2021009528A (es) 2014-09-10 2017-03-08 Prueba de diagnostico basada en fragmento de rgma.

Country Status (10)

Country Link
US (3) US20160069907A1 (es)
EP (1) EP3191847A1 (es)
JP (1) JP6879905B2 (es)
CN (2) CN113267630A (es)
AU (2) AU2015314240A1 (es)
BR (1) BR112017004883A2 (es)
CA (1) CA2956814A1 (es)
MX (2) MX385216B (es)
TW (2) TW201617612A (es)
WO (1) WO2016038084A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
DK2510001T3 (en) * 2009-12-08 2016-02-29 Abbvie Deutschland MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN USED TO TREAT DEGENERATION OF THE RETINAL NERVE FIBER LAYER
JP7150286B2 (ja) 2018-07-19 2022-10-11 国立大学法人 東京大学 Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
EP4091632A4 (en) * 2020-01-15 2024-07-10 Osaka University AGENTS FOR THE PREVENTION OR TREATMENT OF DIABETIC AUTONOMOUS NEUROPATHY
CN112402554B (zh) * 2020-10-26 2022-03-01 中国中医科学院广安门医院 一种治疗脑白质病的中药组合物及其应用
US12306192B2 (en) 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
WO2023004436A1 (en) * 2021-07-23 2023-01-26 Cedars-Sinai Medical Center Methods and systems for early detection of ocular and/or neurological conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
DK2510001T3 (en) * 2009-12-08 2016-02-29 Abbvie Deutschland MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN USED TO TREAT DEGENERATION OF THE RETINAL NERVE FIBER LAYER
KR20170102378A (ko) * 2009-12-09 2017-09-08 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
NZ607480A (en) * 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012047706A2 (en) * 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
EP2723866B1 (en) * 2011-06-22 2018-03-28 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells

Also Published As

Publication number Publication date
MX385216B (es) 2025-03-14
TW202119030A (zh) 2021-05-16
US20160069907A1 (en) 2016-03-10
TW201617612A (zh) 2016-05-16
JP2017526930A (ja) 2017-09-14
US20220018855A1 (en) 2022-01-20
JP6879905B2 (ja) 2021-06-02
AU2015314240A1 (en) 2017-02-09
BR112017004883A2 (pt) 2017-12-05
CN113267630A (zh) 2021-08-17
CN107076757A (zh) 2017-08-18
AU2022200160A1 (en) 2022-02-10
WO2016038084A1 (en) 2016-03-17
US20200241012A1 (en) 2020-07-30
EP3191847A1 (en) 2017-07-19
MX2021009528A (es) 2021-09-08
CA2956814A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
MX2017003063A (es) Prueba de diagnostico basada en fragmento de rgma.
IL261805A (en) Method and apparatus for delivery of therapeutic agents
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
GB201712299D0 (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
EP3307142A4 (en) DEVICE AND METHOD FOR EXAMINING SKIN Lions
DOP2014000174A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
BR112016020051A2 (pt) Aparelho de teste de resistência de aeronave e método de teste de resistência de aeronave
MX368815B (es) Método y dispositivo para analizar relación social.
CO2017002400A2 (es) Composiciones y métodos para detección de proteína smn en un sujeto
PL3117777T3 (pl) Metoda tomografii rozpraszającej i urządzenie do tomografii rozpraszającej
EP3210012C0 (en) Gas testing unit and method
FR3029288B1 (fr) Procede de detection et de caracterisation par ultrasons de defauts dans un materiau heterogene
MX395376B (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2017003513A (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia.
FR3034320B1 (fr) Sonde oculaire de traitement par ultrasons
EP3448980A4 (en) NEW DEVICE AND METHOD FOR DETECTING DISEASES
EP4043859C0 (de) Test- und/oder prüfvorrichtung
EP3350188A4 (en) INHIBITORS OF TRYPTOPHANDIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX2017014857A (es) Metodos para diagnosticar y evaluar tratamiento para sindrome de cushing.
CL2015002779A1 (es) Método para la determinación de la intensidad de la actividad de modificación de los medicamentos bipáticos
EP3236248C0 (en) IONIC CONDUCTIVITY TESTING DEVICE AND TESTING METHOD USING SAME
EA201692432A1 (ru) Способ и устройство для определения времени распадаемости пленочной лекарственной формы
DK3160645T3 (da) Indretning og fremgangsmåde til bestemmelse af en analyt i blod